{"preliminary_commentary":{"by_channel":{"x_thread":5},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["VS-7375"],["VS-7375","cetuximab"],["VS-7375","cetuximab","mFOLFOX6"]],"indication":"metastatic KRAS G12D-mutated colorectal adenocarcinoma","name":"TARGET-D 203","nct_id":"NCT07659795","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=target-d-203-nct07659795. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TARGET-D 203","arms":[{"description":"Participants randomized to a treatment in 2:1 ratio","label":"VS-7375 Monotherapy or Preferred Combination in 2L+ CRC","type":"EXPERIMENTAL"},{"description":null,"label":"VS-7375 with chosen regimen in 2L+ CRC","type":"EXPERIMENTAL"},{"description":null,"label":"VS-7375 + cetuximab and mFOLFOX in 1L CRC","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-12","type":"ESTIMATED"},"conditions":["Colorectal Cancer"],"enrollment":{"count":150,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"VS-7375","otherNames":[],"type":"DRUG"},{"name":"cetuximab","otherNames":[],"type":"DRUG"},{"name":"panitumumab","otherNames":[],"type":"DRUG"},{"name":"Cetuximab + mFOLFOX6","otherNames":[],"type":"DRUG"}],"last_update":"2026-11-18","lead_sponsor":"Verastem, Inc.","official_title":"A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-06","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1 - 2L CRC only","timeFrame":"6 months"},{"measure":"To characterize the safety and tolerability of VS-7375 monotherapy or in combination with cetuximab or panitumumab, administered on a daily oral schedule in participants with KRAS G12D-mutated 2L+ CRC","timeFrame":"6 months"},{"measure":"To characterize the safety and tolerability of VS-7375 in combination with cetuximab + mFOLFOX, administered on a daily oral schedule in participants with KRAS G12D-mutated 1L CRC","timeFrame":"6 months"}],"references":[],"start_date":{"date":"2026-07-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer","url":"https://clinicaltrials.gov/study/NCT07659795"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/target-d-203-nct07659795"}